Intranasal vaccine developer Leyden Laboratories has closed a $140M Series B financing led by Casdin Capital and GV, the company said. Proceeds will go toward development of the company’s pipeline, which includes its PanFlu intranasal mAb vaccine against both influenza A and B. Leyden Labs previously announced a €40 million Series A financing in March 2021.
In July 2021, the company announced that it had entered into an agreement with Nanopharm for development of a liquid nasal vaccine formulation for Phase 1 trials and potentially a powder formulation as well. Leyden Labs says that PanFlu is currently “rapidly moving toward clinical trials.”
Leyden Labs CEO Koenraad Wiedhaup said, “This fundraising underscores our investors’ belief that Leyden Labs’ platform can generate cornerstone products to combat respiratory diseases. The ongoing COVID-19 pandemic teaches us we need to expand our arsenal of tools to fight current and future viral outbreaks. We are very excited to be working with this team of renowned infectious disease scientists and biotechnology leaders to accelerate advancing our platform and product candidates.”
Read the Leyden Laboratories press release.
